Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Ovarian clear cell carcinoma (CCC) is an aggressive subtype known for chemoresistance.
• The AKT signaling pathway is implicated in various cancers, but its role in CCC requires further elucidation.
• Identifying novel therapeutic targets is crucial for improving outcomes in advanced ovarian cancer.

Purpose of the Study:

• To investigate the role of AKT as a therapeutic target in ovarian clear cell carcinoma (CCC).
• To evaluate the efficacy of the AKT inhibitor perifosine in preclinical models of CCC.
• To assess perifosine's activity in chemoresistant and bevacizumab-resistant CCC models.

Main Methods:

• Immunohistochemistry (IHC) was used to assess AKT activation in human ovarian cancer tissue microarrays (CCC and serous adenocarcinoma).
• In vitro and in vivo studies utilized ovarian CCC cell lines and derived tumors to examine perifosine's effects.
• Perifosine's efficacy was tested in tumors resistant to cisplatin or bevacizumab.

Main Results:

• Frequent AKT activation was observed in both early and advanced-stage CCC.
• Perifosine treatment inhibited proliferation, induced apoptosis, and attenuated AKT-mTORC1 signaling in CCC cells.
• CCC with cisplatin resistance showed increased AKT activation and sensitivity to perifosine.
• Combined perifosine and cisplatin treatment enhanced antitumor effects.
• Perifosine demonstrated significant antitumor activity in tumors resistant to bevacizumab or cisplatin.

Conclusions:

• AKT is frequently activated in ovarian CCC and represents a promising therapeutic target.
• AKT-targeted therapy, using agents like perifosine, holds potential as a first-line treatment.
• Perifosine is also valuable as a second-line treatment for recurrent CCC after platinum-based chemotherapy or bevacizumab.